Secondary outcome
PMBL, abdominal pain
ADVERSE EVENT
The mean number of days of use of desloratadine and mometasone furoate per patient was respectively 26% (18.62 ± 4.6 vs 25.2 ± 7.4 days, p = 0.005) and 31% (28.57 ± 7.41 vs 41.6 ± 11.17 days, p < 0.001) lower in the PMBL group vs the placebo group. The therapy was associated with a high safety and tolerability profile. In the PMBL group only one adverse event in forms of mild abdominal pain was reported, which resolved spontaneously without any medication. No adverse event was reported in the placebo group.